CYTEK BIOSCIENCES, INC. Business Acquisition, Pro Forma Revenue
CYTEK BIOSCIENCES, INC. (CTKB) reported Business Acquisition, Pro Forma Revenue of $58.60 million for the 3-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-03-13
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2023-12-31 was $58.60M, a 21.25% increase year-over-year.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2023-09-30 was $48.00M, a 3.40% decline year-over-year.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2023-06-30 was $49.69M, a 1.58% decline year-over-year.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma revenue for the quarter ending 2023-03-31 was $41.66M, a 8.01% decline year-over-year.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma revenue for fiscal 2023 was $197.96M, a 2.14% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma revenue for fiscal 2022 was $193.81M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2023-12-31 | $58.60M 10-K · filed 2024-03-13 | $106.61M derived: sum of 2 quarters · filed 2024-03-13 | $156.30M derived: sum of 3 quarters · filed 2024-03-13 | $197.96M 10-K · filed 2024-03-13 |
| 2023-09-30 | $48.00M 10-Q · filed 2023-11-14 | $97.69M derived: sum of 2 quarters · filed 2023-11-14 | $139.36M 10-Q · filed 2023-11-14 | $187.69M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | $49.69M 10-Q · filed 2023-08-08 | $91.36M 10-Q · filed 2023-08-08 | $139.69M derived: sum of 3 quarters · filed 2024-03-13 | $189.38M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $41.66M 10-Q · filed 2023-05-09 | $90.00M derived: sum of 2 quarters · filed 2024-03-13 | $139.69M derived: sum of 3 quarters · filed 2024-03-13 | $190.18M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | $48.34M 10-K · filed 2024-03-13 | $98.03M derived: sum of 2 quarters · filed 2024-03-13 | $148.52M derived: sum of 3 quarters · filed 2024-03-13 | $193.81M 10-K · filed 2024-03-13 |
| 2022-09-30 | $49.69M 10-Q · filed 2023-11-14 | $100.18M derived: sum of 2 quarters · filed 2023-11-14 | $145.47M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $50.49M 10-Q · filed 2023-08-08 | $95.78M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $45.29M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |